Journal
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
Volume 37, Issue 6, Pages 1686-1696Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/ijmm.2016.2552
Keywords
valproic acid; histone deacetylase inhibitor; acute myeloid leukemia; cytarabine
Categories
Funding
- National Natural Science Foundation of China [81090413, 81270638, 81270567, 81470321, 81300416]
Ask authors/readers for more resources
Acute myeloid leukemia (AML) is an aggressive clonal malignancy of hematopoietic progenitor cells with a poor clinical outcome. The resistance of leukemia cells to contemporary chemotherapy is one of the most formidable obstacles to treating AML. Combining valproic acid (VPA) with other anti-leukemic agents has previously been noted as a useful and necessary strategy which can be used to specifically induce anticancer gene expression. In the present study, we demonstrated the synergistic antileukemic activities between VPA and cytarabine (Ara-C) in a retrovirus-mediated murine model with MLL-AF9 leukemia, three leukemia cell lines (THP-1, K562 and HL-60) and seven primary human AML samples. Using RT-qPCR, we noted that the combination of VPA and Ara-C significantly upregulated BAX expression and led to the arrest of leukemia cell proliferation, sub-G1 DNA accumulation and cell apoptosis, as demonstrated by flow cytometric analysis. Significantly, further experiments revealed that knockdown of BAX expression prevented VPA and Ara-C-induced cell apoptosis in THP-1 cells. The results of our present study demonstrated the synergistic antileukemic effect of combined VPA and Ara-C treatment in AML, and thus we suggest that VPA be used an alternative treatment for AML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available